Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11 | $38 | $29 | $673 |
| - Cash | $15 | $21 | $29 | $32 |
| + Debt | $13 | $12 | $12 | $3 |
| Enterprise Value | $8 | $29 | $12 | $643 |
| Revenue | $9 | $6 | $2 | $1 |
| % Growth | 50.9% | 236.7% | 80.1% | – |
| Gross Profit | $3 | $1 | -$2 | -$2 |
| % Margin | 39.8% | 24.8% | -105.9% | -222.7% |
| EBITDA | -$15 | -$23 | -$27 | -$28 |
| % Margin | -180.7% | -411.4% | -1,607.9% | -2,988.7% |
| Net Income | -$16 | -$24 | -$27 | -$28 |
| % Margin | -193.7% | -423.4% | -1,590.3% | -2,988.5% |
| EPS Diluted | -2.89 | -5.23 | -6.46 | -0.68 |
| % Growth | 44.7% | 19% | -850% | – |
| Operating Cash Flow | -$20 | -$22 | -$24 | -$25 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$20 | -$22 | -$25 | -$26 |